These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 26539624)

  • 1. Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.
    Eaton JS; Miller PE; Mannis MJ; Murphy CJ
    J Ocul Pharmacol Ther; 2015 Dec; 31(10):589-604. PubMed ID: 26539624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).
    Lindgren ES; Yan R; Cil O; Verkman AS; Chan MF; Seitzman GD; Farooq AV; Huppert LA; Rugo HS; Pohlmann PR; Lu J; Esserman LJ; Pasricha ND
    Curr Ophthalmol Rep; 2024 Jun; 12(2):13-22. PubMed ID: 38756824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies.
    Dy GK; Farooq AV; Kang JJ
    Oncologist; 2024 Jul; ():. PubMed ID: 39046895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads.
    Masters JC; Nickens DJ; Xuan D; Shazer RL; Amantea M
    Invest New Drugs; 2018 Feb; 36(1):121-135. PubMed ID: 29027591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
    Leal AD; Krishnamurthy A; Head L; Messersmith WA
    Expert Opin Investig Drugs; 2018 Nov; 27(11):901-916. PubMed ID: 30359534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
    Donaghy H
    MAbs; 2016; 8(4):659-71. PubMed ID: 27045800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care.
    Clark C; Komo I
    Clin J Oncol Nurs; 2024 Mar; 28(2):188-196. PubMed ID: 38511914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Drug Conjugates for Cancer Therapy.
    Polakis P
    Pharmacol Rev; 2016 Jan; 68(1):3-19. PubMed ID: 26589413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates for cancer.
    Chau CH; Steeg PS; Figg WD
    Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates- stability and formulation.
    Duerr C; Friess W
    Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.
    Zhu Y; Liu K; Wang K; Zhu H
    Cancer; 2023 Jan; 129(2):283-295. PubMed ID: 36408673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
    Matulonis UA; Birrer MJ; O'Malley DM; Moore KN; Konner J; Gilbert L; Martin LP; Bauer TM; Oza AM; Malek K; Pinkas J; Kim SK
    Clin Cancer Res; 2019 Mar; 25(6):1727-1736. PubMed ID: 30413525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
    Kamath AV; Iyer S
    Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates: Current status and future perspectives.
    Gébleux R; Casi G
    Pharmacol Ther; 2016 Nov; 167():48-59. PubMed ID: 27492898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
    Chen H; Lin Z; Arnst KE; Miller DD; Li W
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.